BeiGene Q3 Revenue Hits $1.9B Beating Expectations, Non-GAAP EPS Reaches $4.59
nashnova research
BeiGene posted Q3 revenue of $1.9 billion, up 35.7% year-on-year and roughly $140 million above consensus; Non-GAAP EPS came in at $4.59, nearly 2.4 times the Street's $1.88 estimate — Brukinsa is scaling far faster than Wall Street had priced in.
How big was the beat?
Revenue hit $1.9 billion, topping consensus by roughly $140 million with year-on-year growth of 35.7%.
Non-GAAP EPS landed at $4.59 versus the $1.88 estimate — a $2.71 overshoot, nearly 2.4× the forecast.
This means → it was not a marginal beat. Both top and bottom lines blew past expectations, suggesting the Street had systematically underpriced the company's earning power.
What is driving the growth?
The core engine is Brukinsa (zanubrutinib) — a BTK inhibitor used to treat blood cancers.
The drug is now on major formularies across multiple global markets, and its commercial ramp keeps outrunning Wall Street models.
In plain terms = one flagship drug is selling faster than anyone expected, and the momentum is still accelerating.
What does this mean for investors?
A double beat on revenue and profit signals BeiGene has crossed from "burning cash to build a pipeline" into scaled profitability.
This reflects a persistent, systematic underestimate of Chinese innovative pharma companies' ability to commercialize globally.
Key watch-ahead: whether Brukinsa can sustain this growth rate, and when other pipeline assets begin contributing a second growth curve.
市场有风险，内容仅供研究参考，不构成投资建议。